Stockhub

Medigen Biotechnology Corp.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

26 August 2022

  • curprev 06:0506:05, 26 August 2022 >Nick 846 bytes +846 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with radiation for the treatment of esophageal cancer in Japan; is in Phase I clinical t..."
Retrieved from "https://stockhub.co/research/Medigen_Biotechnology_Corp."